 |
 |
January 28, 2007 - February 3, 2007 Israeli Parkinson's patch completes clinical trial Feb. 01 - Israeli company NeuroDerm, Ltd., has completed a pilot clinical trial of ND0601, the first transdermal skin patch for the continuous delivery of levodopa. This drug, which is primarily used in oral form, is the major treatment for Parkinson's disease. Levodopa is the natural precursor of dopamine, a neurotransmitter deficient in the Parkinson's disease brain. The main objective of this GCP compliant pilot study was to assess the pharmacokinetic profile of levodopa in the blood of healthy volunteers following application of ND0601. "I am excited to have started the clinical development of ND0601, a transdermal levodopa patch offering great hope for improving the disabling problems common in advanced Parkinson's disease patients. ND0601 should provide continuous delivery of levodopa in a widely accessible form, a highly sought after treatment option in Parkinson's disease that has been unavailable to date," said Prof. Oded Lieberman, NeuroDerm's chairman. The trial was funded by The Michael J. Fox Foundation for Parkinson's Research through its highly competitive 2006 Clinical Discovery Program. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn